Healthcare Systems Strategy

A Japan-based biopharmaceutical company sought to define a regulatory development pathway for an investigational compound targeting inflammatory bowel disease across US and international markets. The program faced multi-jurisdiction complexity: divergent FDA and PMDA data requirements, evolving indication-specific guidance for IBD therapeutics, and uncertainty regarding clinical trial design acceptable for approval across primary markets. The client required a coordinated regulatory strategy to align clinical investment decisions with the most efficient and defensible path to approval in each jurisdiction.

Innekto Incorporated conducted a cross-jurisdiction regulatory landscape analysis covering FDA, EMA, and PMDA requirements for the IBD indication and adjacent gastrointestinal programs. A US regulatory strategy was designed around an IND filing and Phase 2 clinical pathway, with indication prioritisation informed by development economics, competitive positioning, and probability-of-approval modelling. A pre-IND engagement plan was developed covering clinical trial design, primary endpoint selection, and patient population definition. Parallel EMA and PMDA considerations were mapped, identifying bridging study requirements and jurisdiction-specific data package obligations.

A comprehensive multi-jurisdiction regulatory roadmap was delivered, providing a defined development pathway from IND through NDA/BLA. The strategy identified the US indication with the strongest probability-of-approval profile and the most capital-efficient clinical data package. The resulting framework was directly integrated into investor communications and enabled the client to structure a capital raise to fund the Phase 2 program.

A Singapore-based digital health company operating a cloud-based patient engagement and chronic disease management platform sought entry into the Saudi Arabian market as part of a GCC expansion strategy. The regulatory environment presented significant complexity: the Saudi Food and Drug Authority (SFDA) had recently expanded its digital health notification framework and introduced new AI/ML software classification requirements, and the client had no prior experience engaging GCC health authorities. In addition, the platform required localisation across language, clinical workflow, and data residency dimensions to meet Saudi data sovereignty regulations, which required hosting personal health data within the Kingdom.

Innekto Incorporated conducted a detailed SFDA regulatory classification analysis for each software module, determining notification obligations under the SFDA medical device and digital health frameworks. A compliance roadmap was developed covering technical documentation requirements, registration procedures, and local quality management system (QMS) obligations. A data residency architecture review was conducted in collaboration with the client's engineering team to identify modifications required for Saudi cloud hosting compliance. A local partnership strategy was designed to identify and evaluate potential tier-1 healthcare group partners, with partnership structure and technology licensing terms scoped. Reimbursement positioning and pricing analysis were completed for the primary hospital and primary care segments.

SFDA digital health notification was obtained within eight months of engagement commencement. A strategic platform partnership and licensing agreement was executed with a leading Saudi integrated healthcare group, providing access to a network of hospitals and primary care centres across the Kingdom. Data residency modifications were implemented within the agreed timeline, enabling compliant commercial deployment. Platform revenue in the first year of Saudi operations exceeded the client's internal projections, with contracted expansion to two additional GCC markets initiated in Year 2.